Short Interest in Redhill Biopharma Ltd. (NASDAQ:RDHL) Declines By 36.4%

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a significant decrease in short interest in June. As of June 15th, there was short interest totaling 14,178 shares, a decrease of 36.4% from the May 31st total of 22,308 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily volume of 737,816 shares, the days-to-cover ratio is currently 0.0 days.

Redhill Biopharma Price Performance

Shares of RDHL stock opened at $0.81 on Friday. Redhill Biopharma has a 1 year low of $0.71 and a 1 year high of $3.31. The stock’s 50 day simple moving average is $0.94 and its two-hundred day simple moving average is $1.00. The company has a market cap of $4.22 million, a PE ratio of 0.00 and a beta of 4.98.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Redhill Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Redhill Biopharma stock. Yorkville Advisors Global LP purchased a new position in Redhill Biopharma Ltd. (NASDAQ:RDHL) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma accounts for approximately 0.3% of Yorkville Advisors Global LP’s investment portfolio, making the stock its 19th largest holding. Yorkville Advisors Global LP owned about 7.57% of Redhill Biopharma at the end of the most recent quarter. Institutional investors own 7.20% of the company’s stock.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.